ClinicalTrials.gg
CompletedNCT00307489Updated Nov 1, 2011Results posted

Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil

A Phase 2 interventional study of tenofovir DF and emtricitabine /tenofovir DF in Chronic Hepatitis B, sponsored by Gilead Sciences. Completed at 28 sites in 4 countries. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2011-11-01.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.

Enrollment
30th of 50
106 · median 117
Started
2006
with 1 other
Phase 2
4 of 50
none open now
Registered
4th of 50
by date
Lead sponsor
8 of 50
Gilead Sciences

Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 30th largest by enrollment, is one of 2 that started in 2006, is one of 4 in phase 2, and was the 4th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing tenofovir in Hepatitis B, Chronic as a file.
02

Study summary

This study explores the efficacy, safety and tolerability of tenofovir DF (TDF) 300 mg once daily monotherapy versus the combination of emtricitabine 200 mg plus tenofovir DF 300 mg (FTC/TDF) once daily in subjects currently being treated with adefovir dipivoxil (Hepsera) for chronic hepatitis B who have persistent viral replication (detectable hepatitis B virus deoxyribonucleic acid [HBV DNA]).

Subjects with confirmed (within 4 weeks) plasma HBV DNA ≥ 400 copies/mL during double blind treatment at Week 24 or any time thereafter have the option of receiving 12 weeks of open-label FTC/TDF which may be continued through the end of the 168-week treatment period if there is a virologic response (HBV DNA \< 400 copies/mL). Alternatively, subjects with confirmed HBV DNA \< 400 copies/mL at or any time after Week 24 of double-blind treatment may continue blinded therapy up to Week 168 at the discretion of the investigator. If, in the investigator's opinion, it is felt that continued blinded treatment beyond 24 weeks in subjects with confirmed HBV DNA ≥ 400 copies/mL is not beneficial, the subject may discontinue the study and begin commercially available HBV therapy rather than initiate open-label FTC/TDF.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 through 69 years of age, inclusive
  • Chronic infection, defined as positive serum HBsAg for at least 6 months
  • Active chronic HBV infection with all the following:

    1. Currently treated with adefovir dipivoxil 10 mg QD (for at least 24 weeks but not more than 96 weeks)
    2. HBeAg positive or negative at screening
    3. Plasma HBV DNA >/= 1000 copies/mL at screening (irrespective of HBeAg status)
    4. Serum less than 10 times the (ULN)
    5. Calculated of at least 70 mL/min using the Cockcroft-Gault formula
    6. at least 8 g/dL
    7. Neutrophils at least 1,000 /mm3
  • Nucleoside naive except for lamivudine (>/= 12 weeks of therapy)
  • Negative serum beta human chorionic gonadotropin
  • Compliant with adefovir dipivoxil
  • Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study
  • Male or females of who are unwilling to use an effective method of while enrolled in the study. For males, condoms should be used and for females, a barrier contraception method should be used
  • Decompensated liver disease defined as conjugated greater than 1.5 times , (PT) greater than 1.5 times ULN, less than 75,000/mm3, serum albumin less than 3.0 g/dL, or prior history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, variceal hemorrhage)
  • Prior use of tenofovir DF or entecavir
  • Received treatment with interferon or pegylated interferon within 6 months of the screening visit
  • Evidence of hepatocellular carcinoma (HCC); for example, alpha-fetoprotein greater than 50 ng/mL or by any other standard of care measure.
  • Co-infection with (based on serology), (HIV), or hepatitis delta virus (HDV)
  • Significant renal, cardiovascular, pulmonary, or neurological disease.
  • Received solid organ or bone marrow transplantation.
  • Is currently receiving therapy with immunomodulators (eg, , etc.), agents, nephrotoxic agents, or agents capable of modifying renal excretion
  • Has proximal tubulopathy
  • Known to the study drugs (tenofovir DF or emtricitabine/tenofovir DF), the metabolites (tenofovir or emtricitabine) or formulation
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    1

    TDF

    Drug: tenofovir DF

  • Experimental
    2

    FTC/TDF

    Drug: emtricitabine /tenofovir DF

Interventions

  • 300 mg tablet, once daily (QD)

  • Drugemtricitabine /tenofovir DF

    Drug pages: Emtricitabine · Tenofovir

    emtricitabine 200 mg/tenofovir DF 300 mg once daily (combination tablet)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 48

    Time frame: 48 weeks

  2. Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48

    Time frame: 48 Weeks

Secondary outcomes

  1. Change From Baseline in log10 Plasma HBV DNA Levels at Week 48

    Time frame: 48 Weeks

  2. Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 48

    Time frame: 48 Weeks

  3. Percentage of Participants With Normal ALT at Week 48

    ULN for males = 43 U/L; 34 U/L for females

    Time frame: 48 Weeks

  4. Percentage of Participants With Normalized ALT at Week 48

    Subjects with elevated ALT at baseline that return to normal by Week 48.

    Time frame: 48 Weeks

  5. Hepatitis B Early Antigen (HBeAg) Loss at Week 48

    Defined as having negative serum HBeAg for subjects with positive HBeAg at baseline.

    Time frame: 48 Weeks

  6. HBeAg Seroconversion at Week 48

    Defined as having negative serum HBeAg and positive serum antibody to HBeAg \[anti-HBe\] for subjects with positive serum HBeAg at baseline.

    Time frame: 48 Weeks

  7. HBsAg Loss at Week 48

    Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline.

    Time frame: 48 Weeks

  8. Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 48

    Defined as having negative serum HBsAg and positive serum antibody to HBsAg \[anti-HBs\] for subject with positive serum HBsAg at baseline.

    Time frame: 48 Weeks

  9. Change From Baseline in log10 Plasma HBV DNA Levels at Week 168

    Time frame: 168 weeks

  10. Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 168

    Time frame: 168 weeks

  11. Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168

    Time frame: 168 weeks

  12. Percentage of Participants With Normal ALT at Week 168

    ULN for males = 43 U/L; ULN for females = 34 U/L

    Time frame: 168 weeks

  13. Percentage of Participants With Normalized ALT at Week 168

    Subjects with elevated ALT at baseline that return to normal by Week 48.

    Time frame: 168 weeks

  14. Hepatitis B Early Antigen (HBeAg) Loss at Week 168

    Defined as having negative serum HBeAg for subjecst with positive HBeAg at baseline.

    Time frame: 168 weeks

  15. Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 168

    Defined as having negative serum BHsAg and positive serum antibody to HBsAg (anti-HBs) for subject with positive serum BHsAg at baseline.

    Time frame: 168 weeks

  16. HBsAg Loss at Week 168

    Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline.

    Time frame: 168 weeks

  17. Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 168

    P-values were from a Cochran-Mantel-Haenszel test, controlling for baseline HBeAg status and prior lamivudine use.

    Time frame: 168 weeks

07

Results

Posted Jul 7, 2009
Limitations and caveats
The randomized and treated (RAT) analysis set includes all subjects who were ongoing at the time of analysis (i.e., those on blinded therapy and those who switched to open-label FTC/TDFdue to persistent viremia).

Participant flow

A total of 106 subjects were randomized (105 of which were subsequently treated) across 28 study centers in the US, Germany, France and Spain between 24 April 2006 and 07 March 2007.

Baseline Through Week 48
Participant flow — Baseline Through Week 48
MilestoneTenofovir DFEmtricitibine/Tenofovir DF
Started5352
Completed5250
Not completed12
Withdrew: Lost to follow-up01
Withdrew: Physician decision10
Withdrew: Withdrawal by subject01
Week 48 Through Week 168
Participant flow — Week 48 Through Week 168
MilestoneTenofovir DFEmtricitibine/Tenofovir DF
Started5250
Completed4644
Not completed66
Withdrew: Adverse event10
Withdrew: Physician decision10
Withdrew: Withdrawal by subject12
Withdrew: Lack of efficacy22
Withdrew: Death01
Withdrew: Lost to follow-up01
Withdrew: Seroconversion10

Outcome measures

PrimaryPercentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 48
Time frame:
48 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 48
percentage of participantsTenofovir DFEmtricitibine/Tenofovir DF
Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 4875.569.2
Statistical analysis
  • Tenofovir DF vs Emtricitibine/Tenofovir DF · Cochran-Mantel-Haenszel · p = .544 (P-values were from a Cochran-Mantel-Haenszel test, controlling for baseline HBeAg status and prior lamivudine use.)
SecondaryChange From Baseline in log10 Plasma HBV DNA Levels at Week 48
Time frame:
48 Weeks
Reported as:
Mean · log10 copies/mL
Change From Baseline in log10 Plasma HBV DNA Levels at Week 48
log10 copies/mLTenofovir DFEmtricitibine/Tenofovir DF
Change From Baseline in log10 Plasma HBV DNA Levels at Week 48-3.58 ± 1.290-3.34 ± 1.753
Statistical analysis
  • Tenofovir DF vs Emtricitibine/Tenofovir DF · van Elteren · p = 0.208 (Controlling for baseline HBeAg status and prior lamivudine use.)
SecondaryChange From Baseline in Alanine Aminotransferase (ALT) Levels at Week 48
Time frame:
48 Weeks
Reported as:
Mean · U/mL
Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 48
U/mLTenofovir DFEmtricitibine/Tenofovir DF
Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 48-21.6 ± 54.53-41.4 ± 151.67
Statistical analysis
  • Tenofovir DF vs Emtricitibine/Tenofovir DF · van Elteren · p = 0.712 (Controlling for baseline HBeAg and prior lamivudine use.)
PrimaryPercentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48
Time frame:
48 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48
percentage of participantsTenofovir DFEmtricitibine/Tenofovir DF
Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 4881.180.8
Statistical analysis
  • Tenofovir DF vs Emtricitibine/Tenofovir DF · Cochran-Mantel-Haenszel · p = 0.988 (Controlling for baseline HBeAg status and prior lamivudine use.)
SecondaryPercentage of Participants With Normal ALT at Week 48

ULN for males = 43 U/L; 34 U/L for females

Time frame:
48 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Normal ALT at Week 48
percentage of participantsTenofovir DFEmtricitibine/Tenofovir DF
Percentage of Participants With Normal ALT at Week 4866.773.1
Statistical analysis
  • Tenofovir DF vs Emtricitibine/Tenofovir DF · Cochran-Mantel-Haenszel · p = 0.423 (Controlling for baseline HBeAg status and prior lamivudine use)
SecondaryPercentage of Participants With Normalized ALT at Week 48

Subjects with elevated ALT at baseline that return to normal by Week 48.

Time frame:
48 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Normalized ALT at Week 48
percentage of participantsTenofovir DFEmtricitibine/Tenofovir DF
Percentage of Participants With Normalized ALT at Week 4840.761.5
Statistical analysis
  • Tenofovir DF vs Emtricitibine/Tenofovir DF · Cochran-Mantel-Haenszel · p = 0.109 (Controlling for baseline HBeAg status and prior lamivudine use.)
SecondaryHepatitis B Early Antigen (HBeAg) Loss at Week 48

Defined as having negative serum HBeAg for subjects with positive HBeAg at baseline.

Time frame:
48 Weeks
Reported as:
Number · participants
Hepatitis B Early Antigen (HBeAg) Loss at Week 48
participantsTenofovir DFEmtricitibine/Tenofovir DF
Hepatitis B Early Antigen (HBeAg) Loss at Week 4833
Statistical analysis
  • Tenofovir DF vs Emtricitibine/Tenofovir DF · Cochran-Mantel-Haenszel · p = 0.952Controlling for baseline HBeAg and prior lamivudine use.
SecondaryHBeAg Seroconversion at Week 48

Defined as having negative serum HBeAg and positive serum antibody to HBeAg \[anti-HBe\] for subjects with positive serum HBeAg at baseline.

Time frame:
48 Weeks
Reported as:
Number · participants
HBeAg Seroconversion at Week 48
participantsTenofovir DFEmtricitibine/Tenofovir DF
HBeAg Seroconversion at Week 4823
Statistical analysis
  • Tenofovir DF vs Emtricitibine/Tenofovir DF · Cochran-Mantel-Haenszel · p = 0.655 (Controlling for baseline HBeAg status and prior lamivudine use.)
SecondaryHBsAg Loss at Week 48

Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline.

Time frame:
48 Weeks
Reported as:
Number · participants
HBsAg Loss at Week 48
participantsTenofovir DFEmtricitibine/Tenofovir DF
HBsAg Loss at Week 4810
Statistical analysis
  • Tenofovir DF vs Emtricitibine/Tenofovir DF · Cochran-Mantel-Haenszel · p = 0.401 (Controlling for baseline HBeAg status and prior lamivudine use.)
SecondaryHepatitis B Surface Antigen (HBsAg) Seroconversion at Week 48

Defined as having negative serum HBsAg and positive serum antibody to HBsAg \[anti-HBs\] for subject with positive serum HBsAg at baseline.

Time frame:
48 Weeks
Reported as:
Number · participants
Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 48
participantsTenofovir DFEmtricitibine/Tenofovir DF
Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 4810
Statistical analysis
  • Tenofovir DF vs Emtricitibine/Tenofovir DF · Cochran-Mantel-Haenszel · p = 0.401 (Controlling for baseline HBeAg status and prior lamivudine use.)
SecondaryChange From Baseline in log10 Plasma HBV DNA Levels at Week 168
Time frame:
168 weeks
Reported as:
Mean · log10 copies/mL
Change From Baseline in log10 Plasma HBV DNA Levels at Week 168
log10 copies/mLTenofovir DFEmtricitibine/Tenofovir DF
Change From Baseline in log10 Plasma HBV DNA Levels at Week 168-3.79 ± 1.305-3.48 ± 1.629
Statistical analysis
  • Tenofovir DF vs Emtricitibine/Tenofovir DF · van Elteren · p = 0.103 (Controlling for baseline HBeAg status and prior lamivudine use.)
SecondaryChange From Baseline in Alanine Aminotransferase (ALT) Levels at Week 168
Time frame:
168 weeks
Reported as:
Mean · U/mL
Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 168
U/mLTenofovir DFEmtricitibine/Tenofovir DF
Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 168-26.8 ± 60.23-54.5 ± 141.63
Statistical analysis
  • Tenofovir DF vs Emtricitibine/Tenofovir DF · van Elteren · p = 0.999 (Controlling for baseline HBeAg status and prior lamivudine use.)
SecondaryPercentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168
Time frame:
168 weeks
Reported as:
Number · Percent of Participants
Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168
Percent of ParticipantsTenofovir DFEmtricitibine/Tenofovir DF
Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 16882.484.0
Statistical analysis
  • Tenofovir DF vs Emtricitibine/Tenofovir DF · Cochran-Mantel-Haenszel · p = 0.781 (Controlling for baseline HBeAg status and prior lamivudine use.)
SecondaryPercentage of Participants With Normal ALT at Week 168

ULN for males = 43 U/L; ULN for females = 34 U/L

Time frame:
168 weeks
Reported as:
Number · Percent of Participants
Percentage of Participants With Normal ALT at Week 168
Percent of ParticipantsTenofovir DFEmtricitibine/Tenofovir DF
Percentage of Participants With Normal ALT at Week 16874.074.0
Statistical analysis
  • Tenofovir DF vs Emtricitibine/Tenofovir DF · Cochran-Mantel-Haenszel · p = 0.936 (Controlling for baseline HBeAg status and prior lamivudine use.)
SecondaryPercentage of Participants With Normalized ALT at Week 168

Subjects with elevated ALT at baseline that return to normal by Week 48.

Time frame:
168 weeks
Reported as:
Number · Percent of Participants
Percentage of Participants With Normalized ALT at Week 168
Percent of ParticipantsTenofovir DFEmtricitibine/Tenofovir DF
Percentage of Participants With Normalized ALT at Week 16868.070.8
Statistical analysis
  • Tenofovir DF vs Emtricitibine/Tenofovir DF · Cochran-Mantel-Haenszel · p = 0.784 (Controlling for baseline HBeAg status and prior lamivudine use.)
SecondaryHepatitis B Early Antigen (HBeAg) Loss at Week 168

Defined as having negative serum HBeAg for subjecst with positive HBeAg at baseline.

Time frame:
168 weeks
Reported as:
Number · Percent of Participants
Hepatitis B Early Antigen (HBeAg) Loss at Week 168
Percent of ParticipantsTenofovir DFEmtricitibine/Tenofovir DF
Hepatitis B Early Antigen (HBeAg) Loss at Week 16821.624.3
Statistical analysis
  • Tenofovir DF vs Emtricitibine/Tenofovir DF · Cochran-Mantel-Haenszel · p = 0.703 (Controlling for baseline HBeAg status and prior lamivudine use.)
SecondaryHepatitis B Surface Antigen (HBsAg) Seroconversion at Week 168

Defined as having negative serum BHsAg and positive serum antibody to HBsAg (anti-HBs) for subject with positive serum BHsAg at baseline.

Time frame:
168 weeks
Reported as:
Number · Participants
Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 168
ParticipantsTenofovir DFEmtricitibine/Tenofovir DF
Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 16810
Statistical analysis
  • Tenofovir DF vs Emtricitibine/Tenofovir DF · Cochran-Mantel-Haenszel · p = 0.254 (Controlling for baseline HBeAg status and prior lamivudine use.)
SecondaryHBsAg Loss at Week 168

Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline.

Time frame:
168 weeks
Reported as:
Number · Participants
HBsAg Loss at Week 168
ParticipantsTenofovir DFEmtricitibine/Tenofovir DF
HBsAg Loss at Week 16810
Statistical analysis
  • Tenofovir DF vs Emtricitibine/Tenofovir DF · Cochran-Mantel-Haenszel · p = 0.254 (Controlling for baseline HBeAg status and prior lamivudine use.)
SecondaryPercentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 168

P-values were from a Cochran-Mantel-Haenszel test, controlling for baseline HBeAg status and prior lamivudine use.

Time frame:
168 weeks
Reported as:
Number · Percent of Participants
Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 168
Percent of ParticipantsTenofovir DFEmtricitibine/Tenofovir DF
Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 16880.478.0
Statistical analysis
  • Tenofovir DF vs Emtricitibine/Tenofovir DF · Cochran-Mantel-Haenszel · p = 0.878

Adverse events

Collected over 168 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tenofovir DF———
Emtricitibine/Tenofovir DF———
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventTenofovir DFEmtricitibine/Tenofovir DF
Alanine Aminotransferase IncreasedInvestigations0/532/52
AlcoholismPsychiatric disorders0/531/52
AppendicitisInfections and infestations0/531/52
Atrial FibrillationCardiac disorders0/531/52
BartholinitisReproductive system and breast disorders0/531/52
Cerebrovascular AccidentNervous system disorders0/531/52
Chronic SinusitisInfections and infestations0/531/52
Fibroadenoma of BreastNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/531/52
HemiparesisNervous system disorders0/531/52
LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/531/52
Most frequent other events
Showing 10 of 33
Most frequent other events
EventTenofovir DFEmtricitibine/Tenofovir DF
NasopharyngitisInfections and infestations16/5312/52
HeadacheNervous system disorders15/5310/52
Abdominal Pain UpperGastrointestinal disorders8/539/52
FatigueGeneral disorders9/539/52
Back PainMusculoskeletal and connective tissue disorders9/536/52
Pharyngolaryngeal PainRespiratory, thoracic and mediastinal disorders8/533/52
BronchitisInfections and infestations3/537/52
AstheniaGeneral disorders7/532/52
Abdominal PainGastrointestinal disorders5/535/52
ArthralgiaMusculoskeletal and connective tissue disorders2/535/52

Baseline characteristics

Age Continuous
Age Continuous(years)Tenofovir DFEmtricitibine/Tenofovir DFTotal
Mean40 ± 11.439 ± 10.439 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Tenofovir DFEmtricitibine/Tenofovir DFTotal
Female151025
Male384280
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tenofovir DFEmtricitibine/Tenofovir DFTotal
Asian261844
Black or African American2810
White232144
Other257
Previous Lamivudine Experience
Previous Lamivudine Experience(participants)Tenofovir DFEmtricitibine/Tenofovir DFTotal
Yes303161
No232144
Baseline HBV DNA
Baseline HBV DNA(log10 copies/mL)Tenofovir DFEmtricitibine/Tenofovir DFTotal
Mean6.06 ± 1.4305.87 ± 1.7795.97 ± 1.607
08

Study locations

28 sites
  • San Francisco, California 94115, United States
  • San Jose, California 95128, United States
  • Flushing, New York 11355, United States
  • New York, New York 10013, United States
  • New York, New York 10016, United States
  • New York, New York 10021, United States
  • Philadelphia, Pennsylvania 19107, United States
  • Fairfax, Virginia 22031, United States
  • Norfolk, Virginia 23502, United States
  • Richmond, Virginia 23249, United States
  • Angers, 49933, France
  • Clichy, 92110, France
  • Lille, 59037, France
  • Lyon, 69288, France
  • Marseille, 13285, France
  • Rouen, 76031, France
  • Strasbourg, 67091, France
  • Berlin, 10969, Germany
  • Berlin, 13353, Germany
  • Bonn, 53105, Germany
  • Erlangen, 91054, Germany
  • Essen, 45122, Germany
  • Frankfurt, 60590, Germany
  • Hamburg, 20999, Germany
  • Hannover, 30623, Germany
  • Herne, 44623, Germany
  • Munchen, 81377, Germany
  • Sevilla, 41014, Spain
09

References and documents

Publications

  • van Bommel F, Zollner B, Sarrazin C, Spengler U, Huppe D, Moller B, Feucht HH, Wiedenmann B, Berg T. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006 Aug;44(2):318-25. doi: 10.1002/hep.21253. PubMed 16871563 ↗
  • Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008 Dec 4;359(23):2442-55. doi: 10.1056/NEJMoa0802878. PubMed 19052126 ↗
  • Reijnders JG, Janssen HL. Potency of tenofovir in chronic hepatitis B: mono or combination therapy? J Hepatol. 2008 Mar;48(3):383-6. doi: 10.1016/j.jhep.2007.12.006. Epub 2007 Dec 31. No abstract available. PubMed 18191272 ↗
  • Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol. 2008 Mar;48(3):391-8. doi: 10.1016/j.jhep.2007.09.020. Epub 2008 Jan 3. PubMed 18199519 ↗
  • van Bommel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Huppe D, Stein K, Trojan J, Sarrazin C, Bocher WO, Spengler U, Wasmuth HE, Reinders JG, Moller B, Rhode P, Feucht HH, Wiedenmann B, Berg T. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010 Jan;51(1):73-80. doi: 10.1002/hep.23246. PubMed 19998272 ↗
  • Berg T, Marcellin P, Zoulim F, Moller B, Trinh H, Chan S, Suarez E, Lavocat F, Snow-Lampart A, Frederick D, Sorbel J, Borroto-Esoda K, Oldach D, Rousseau F. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology. 2010 Oct;139(4):1207-17. doi: 10.1053/j.gastro.2010.06.053. Epub 2010 Jun 20. PubMed 20600025 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of Jan 2008 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2006
First posted
Mar 28, 2006
Start
Mar 2006
Primary completionActual
Jan 2008
CompletionActual
Oct 2010
Results first posted
Jul 7, 2009
Last update
Nov 1, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00307489
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 28, 2006
Start date
Mar 2006
Primary completion
Jan 2008
Completion
Oct 2010
Results posted
Jul 7, 2009
Last update
Nov 1, 2011

Study contacts

Stephen J Rossi, PharmD
study director · Gilead Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tenofovir · Emtricitabine

Start the discussion